Bank of America
PCVX icon

Bank of America’s Vaxcyte PCVX Stock Holding History

Bank of America’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$62.7M Sell
1,078,798
-138,045
-11% -$7.5M ﹤0.01% 1528
2026
Q1 		$70.7M Buy
1,216,843
+515,209
+73% +$28M 0.01% 1369
2025
Q4 		$32.4M Buy
701,634
+66,564
+10% +$2.98M ﹤0.01% 1890
2025
Q3 		$22.9M Sell
635,070
-447,601
-41% -$14.8M ﹤0.01% 2498
2025
Q2 		$35.2M Buy
1,082,671
+291,859
+37% +$9.57M ﹤0.01% 2008
2025
Q1 		$29.9M Buy
790,812
+320,901
+68% +$25.7M ﹤0.01% 2050
2024
Q4 		$38.5M Sell
469,911
-99,979
-18% -$9.93M ﹤0.01% 1725
2024
Q3 		$65.1M Buy
569,890
+98,609
+21% +$8.89M 0.01% 1349
2024
Q2 		$35.6M Buy
471,281
+185,405
+65% +$12.6M ﹤0.01% 1728
2024
Q1 		$19.5M Buy
285,876
+111,725
+64% +$7.74M ﹤0.01% 2309
2023
Q4 		$10.9M Sell
174,151
-35,982
-17% -$1.87M ﹤0.01% 2791
2023
Q3 		$10.7M Sell
210,133
-30,970
-13% -$1.53M ﹤0.01% 2652
2023
Q2 		$12M Sell
241,103
-43,006
-15% -$2.04M ﹤0.01% 2530
2023
Q1 		$10.6M Sell
284,109
-12,510
-4% -$531K ﹤0.01% 2759
2022
Q4 		$14.2M Buy
296,619
+190,164
+179% +$7.46M ﹤0.01% 2335
2022
Q3 		$2.56M Buy
106,455
+10,151
+11% +$257K ﹤0.01% 4055
2022
Q2 		$2.1M Buy
96,304
+57,826
+150% +$1.34M ﹤0.01% 4259
2022
Q1 		$929K Sell
38,478
-36,589
-49% -$799K ﹤0.01% 5346
2021
Q4 		$1.78M Buy
75,067
+46,834
+166% +$1.09M ﹤0.01% 4673
2021
Q3 		$716K Sell
28,233
-50,378
-64% -$1.22M ﹤0.01% 5355
2021
Q2 		$1.77M Buy
78,611
+29,344
+60% +$601K ﹤0.01% 4434
2021
Q1 		$973K Buy
49,267
+45,741
+1,297% +$1.15M ﹤0.01% 4849
2020
Q4 		$93K Sell
3,526
-179
-5% -$6.66K ﹤0.01% 6023
2020
Q3 		$183K Buy
3,705
+3,505
+1,753% +$140K ﹤0.01% 5353
2020
Q2 		$6K Buy
+200
New +$6.43K ﹤0.01% 6537

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Bank of America's PCVX Position: Q2 2026 in Review

Bank of America reduced its Vaxcyte (PCVX) stake by 11% in Q2 2026, selling an estimated $7.5M and leaving 1,078,798 shares worth $62.7M. The position accounts for ﹤0.01% of the portfolio, ranked #1528.

Bank of America first reported a position in PCVX in Q2 2020 and has held it in 25 quarters since. The position peaked at $70.7M in Q1 2026. 332 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • Bank of America held 1,078,798 shares of Vaxcyte worth $62.7M as of Q2 2026.
  • Bank of America sold 138,045 Vaxcyte shares in Q2 2026, an estimated $7.5M.
  • Vaxcyte made up ﹤0.01% of Bank of America's portfolio in Q2 2026, its #1528 holding.
  • Bank of America first reported a position in Vaxcyte in Q2 2020 and has held it in 25 quarters since.
  • Bank of America's Vaxcyte position peaked at $70.7M in Q1 2026.
  • 332 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Bank of America's 13F filing for Q2 2026, filed 14 Aug 2026.